Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes

Radiation Research

Volumn 173, Issue 4, 2010, Pages 505-511

  Alsbeih, G ^a   Al Harbi, N ^a   Al Hadyan, K ^a   El Sebaie, M ^a   Al Rajhi, N ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOLOGICAL MARKER; GLUTAMINE; LEUCINE; METHIONINE; PROLINE; THREONINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CODON; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; FIBROSIS; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PILOT STUDY; PRIORITY JOURNAL; RADIOSENSITIVITY; SINGLE NUCLEOTIDE POLYMORPHISM; TGFB1 GENE; WILD TYPE; XRCC1 GENE; XRCC3 GENE;

ADOLESCENT; ADULT; AGED; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIATION PNEUMONITIS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950208798     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1769.1     Document Type: Article

References (32)

1. L. J. Peters, Radiation therapy tolerance limits. For one or for all? Cancer 77, 2379-2385 (1996).
2. S. L. Tucker, F. B. Geara, L. J. Peters and W. A. Brock, How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity? Radiother. Oncol. 38, 103-113 (1996).
3. D. Guirado and J. M. Ruiz de Almodovar, Prediction of normal tissue response and individualization of doses in radiotherapy. Phys. Med. Biol. 48, 3213-3223 (2003).
4. R. M. Hart, B. F. Kimler, R. G. Evans and C. H. Park, Radiotherapeutic management of medulloblastoma in a pediatric patient with ataxia telangiectasia. Int. J. Radiat. Oncol. Biol. Phys. 13, 1237-1240 (1987).
5. G. Alsbeih, M. D. Story, M. H. Maor, F. B. Geara and W. A. Brock, Chromosomal fragility syndrome and family history of radiosensitivity as indicators for radiotherapy dose modification. Radiother. Oncol. 66, 341-344 (2003).
6. I. Turesson, J. Nyman, E. Holmberg and A. Oden, Prognostic factors for acute and late skin reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. 36, 1065-1075 (1996).
7. K. Savitsky, A. Bar-Shira, S. Gilad, G. Rotman, Y. Ziv, L. Vanagaite, D. A. Tagle, S. Smith, T. Uziel and Y. Shiloh, A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753 (1995).
8. E. Riballo, S. E. Critchlow, S. H. Teo, A. J. Doherty, A. Priestley, B. Broughton, B. Kysela, H. Beamish, N. Plowman and P. A. Jeggo, Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr. Biol. 9, 699-702 (1999).
9. R. Varon, C. Vissinga, M. Platzer, K. M. Cerosaletti, K. H. Chrzanowska, K. Saar, G. Beckmann, E. Seemanova, P. R. Cooper and A. Reis, Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93, 467-476 (1998).
10. M. Fernet, M. Gribaa, M. A. Salih, M. Z. Seidahmed, J. Hall and M. Koenig, Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder. Hum. Mol. Genet. 14, 307-318 (2005).
11. C. N. Andreassen, J. Alsner and J. Overgaard, Does variability in normal tissue reactions after radiotherapy have a genetic basis\ where and how to look for it? Radiother. Oncol. 64, 131-140 (2002).
12. C. N. Andreassen, J. Alsner, M. Overgaard and J. Overgaard, Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother. Oncol. 69, 127-135 (2003).
13. C. N. Andreassen, Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Acta Oncol. 44, 801-815 (2005).
14. C. N. Andreassen, J. Overgaard, J. Alsner, M. Overgaard, C. Herskind, J. A. Cesaretti, D. P. Atencio, S. Green, S. C. Formenti and B.S. Rosenstein, ATM sequence variants and riskof radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 64, 776-783 (2006).
15. A. Al-Amro, N. Al-Rajhi, Y. Khafaga, M. Memon, A. Al-Hebshi, A. El-Enbabi, G. El-Husseiny, A. Radawi, A. Belal and M. El-Sebaie, Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 62, 508-513 (2005).
16. G. Alsbeih, M. El-Sebaie, N. El-Rajhi, A. Allam, M. Al-Buhairi, N. Al-Harbi, Y. Khafaga, M. Alsubael and M. Al-Shabanah, Relationship between radiosensitivity and normal tissue complications in Saudi cancer patients treated with radiotherapy. J. Egypt. Natl. Cancer Inst. 16, 216-223 (2004).
17. R. Brem and J. Hall, XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res. 33, 2512-2520 (2005).
18. R. M. Taylor, A. Thistlethwaite and K. W. Caldecott, Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol. Cell Biol. 22, 2556-2563 (2002).
19. R. Brem, D. G. Cox, B. Chapot, N. Moullan, P. Romestaing, J. P. Gerard, P. Pisani and J. Hall, The XRCC1-77TRC variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 27, 2469-2474 (2006).
20. C. N. Andreassen, J. Alsner, J. Overgaard, C. Herskind, J. Haviland, R. Owen, J. Homewood, J. Bliss and J. Yarnold, TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother. Oncol. 75, 18-21 (2005).
21. S. Quarmby, H. Fakhoury, E. Levine, J. Barber, J. Wylie, A. H. Hajeer, C. West, A. Stewart, B. Magee and S. Kumar, Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int. J. Radiat. Biol. 79, 137-143 (2003).
22. K. De Ruyck, M. Van Eijkeren, K. Claes, K. Bacher, A. Vral, W. De Neve and H. Thierens, TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int. J. Radiat. Oncol. Biol. Phys. 65, 1240-1248 (2006).
23. C. N. Andreassen, J. Alsner, M. Overgaard, F. B. Sorensen and J. Overgaard, Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM\a study based on DNA from formalin fixed paraffin embedded tissue samples. Int. J. Radiat. Biol. 82, 577-586 (2006).
24. S. Damaraju, D. Murray, J. Dufour, D. Carandang, S. Myrehaug, G. Fallone, C. Field, R. Greiner, J. Hanson and M. Parliament, Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin. Cancer Res. 12, 2545-2554 (2006).
25. W. A. Border and N. A. Noble, Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292 (1994).
26. A. M. Dunning, P. D. Ellis, S. McBride, H. L. Kirschenlohr, C. S. Healey, P. R. Kemp, R. N. Luben, J. Chang-Claude, A. Mannermaa and J. C. Metcalfe, A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 63, 2610-2615 (2003).
27. C. Li, P. B. Wilson, E. Levine, J. Barber, A. L. Stewart and S. Kumar, TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int. J. Cancer 84, 155-159 (1999).
28. C. E. Rube, J. Palm, M. Erren, J. Fleckenstein, J. Konig, K. Remberger and C. Rube, Cytokine plasma levels: reliable predictors for radiation pneumonitis? PLoS ONE 3, e2898 (2008).
29. K. De Jaeger, Y. Seppenwoolde, H. H. Kampinga, L. J. Boersma, J. S. Belderbos and J. V. Lebesque, Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 1378-1387 (2004).
30. G. Alsbeih, M. El-Sebaie, N. Al-Harbi, M. Al-Buhairi, K. Al-Hadyan and N. Al-Rajhi, Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int. J. Radiat. Oncol. Biol. Phys. 68, 229-235 (2007).
31. X. Yuan, Z. Liao, Z. Liu, L. E. Wang, S. L. Tucker, L. Mao, X. S. Wang, M. Martel, R. Komaki and Q. Wei, Single nucleotide polymorphism at rs1982073:T869C of the TGFb1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J. Clin. Oncol. 27, 3370-3378 (2009).
32. G. Matullo, S. Guarrera, S. Carturan, M. Peluso, C. Malaveille, L. Davico, A. Piazza and P. Vineis, DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int. J. Cancer 92, 562-567 (2001).